HUTCHMED Initiates the RAPHAEL Registrational Phase III Tria

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

China , Hong Kong , Peking , Beijing , Shanghai , Chinese , Ben Atwell Alex Shaw , Ann Hematol , Xiaojun Huang , Zhou Yi , Atholl Tweedie , China Limited , Nasdaq , University People Hospital , Drug Administration , Exchange Commission , European Hematology Association Congress , Stock Exchange Of Hong Kong , National Cancer Institute , Linkedin , Prof Xiaojun Huang , Peking University People , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , Alex Shaw , Dual Inhibitor , Mutant Isocitrate Dehydrogenase , Acquired Resistance ,